“…This suggests that NRL001 is worthy of clinical investigation in Phase II patient populations with passive faecal incontinence. [25] A randomised, controlled, crossover study to investigate the safety and response of 1R,2S-methoxamine hydrochloride (NRL001) on anal function in healthy volunteers SUSD [26] Randomised clinical trial: study of escalating doses of NRL001 given in rectal suppositories of different weights SAGE [27] A randomised, controlled, crossover study to investigate the pharmacodynamics, pharmacokinetics and safety of 1R,2S-methoxamine hydrochloride (NRL001) in healthy elderly subjects SURD [28] A double-blind, placebo-controlled, randomised, parallel-group, doseescalating, repeat dose study in healthy volunteers to evaluate the safety, tolerability, pharmacodynamic effects and pharmacokinetics of the once daily rectal application of NRL001 suppositories for 14 days Meta-analysis [29] Meta-analysis for cardiovascular effects of NRL001 after rectal application in healthy volunteers…”